{
  "objCls" : "Guideline",
  "@id" : "https://www.pharmgkb.org/data/guideline/PA166104935",
  "@context" : "https://www.pharmgkb.org/jsonld/guideline.jsonld",
  "id" : "PA166104935",
  "name" : "Dutch Pharmacogenetics Working Group Guideline for clozapine and CYP2D6",
  "relatedDrugs" : [ {
    "objCls" : "Drug",
    "@id" : "https://www.pharmgkb.org/data/drug/PA449061",
    "@context" : "https://www.pharmgkb.org/jsonld/drug.jsonld",
    "id" : "PA449061",
    "name" : "clozapine"
  } ],
  "relatedGenes" : [ {
    "objCls" : "Gene",
    "@id" : "https://www.pharmgkb.org/data/gene/PA128",
    "@context" : "https://www.pharmgkb.org/jsonld/gene.jsonld",
    "id" : "PA128",
    "symbol" : "CYP2D6",
    "name" : "cytochrome P450, family 2, subfamily D, polypeptide 6"
  } ],
  "source" : "DPWG",
  "summaryHtml" : "<p>There are currently no dosing recommendations for Clozapine based on CYP2D6 genotypes.</p>",
  "textHtml" : "<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for clozapine based on CYP2D6 genotypes [Article:<a href=\"/pmid/21412232\">21412232</a>].  They conclude that there are no recommendations at this time.</p><table class=\"table table-striped table-condensed table-hover table-bordered\"><tr><th> Phenotype (Genotype) </th><th> Therapeutic Dose Recommendation </th><th> Level of Evidence </th><th> Clinical Relevance </th></tr><tr><td> PM (two inactive (*3-*8, *11-*16, *19-*21, *38, *40, *42) alleles) </td><td> No recommendations. </td><td> Published controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints. </td><td> Clinical effect (not statistically significant difference). </td></tr><tr><td> IM (two decreased-activity (*9, *10, *17, *29, *36, *41) alleles or carrying one active (*1, *2, *33, *35) and one inactive (*3-*8, *11-*16, *19-*21, *38, *40, *42) allele, or carrying one decreased-activity (*9, *10, *17, *29, *36, *41) allele and one inactive (*3-*8, *11-*16, *19-*21, *38, *40, *42) allele) </td><td> No recommendations. </td><td> Published controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints. </td><td>Clinical effect (not statistically significant difference). </td></tr><tr><td> UM (a gene duplication in absence of inactive (*3-*8, *11-*16, *19-*21, *38, *40, *42) or decreased-activity (*9, *10, *17, *29, *36, *41) alleles) </td><td>No recommendations. </td><td> Published controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints. </td><td> Clinical effect (not statistically significant difference). </td></tr></table><ul><li>*See <a href=\"http://www.pharmgkb.org/home/dutch_pharmacogenetics_working_group.jsp\">Methods</a> or <a href=\"http://www.pharmgkb.org/pmid/18253145\">PMID: 18253145</a> for definition of \"good quality.\"</li><li>Please see attached PDF for detailed information about the evaluated studies: <a href=\"/download.do?objCls=Attachment&amp;objId=clozapine_CYP2D6_271111.pdf\" title=\"link tip\">Clozapine CYP2D6</a></li></ul>"
}